eli lilly retatrutide clinical trials Phase 3 obesity trial results 2026 Eli Lilly's retatrutide shows efficacy

Ozempic & GLP-1 Weight Loss Drug Lawsuit Attorneys Home \ New York Personal Injury Lawyer \ New York Ozempic & GLP-1 Weight Loss Drug Lawsuit Attorneys John Richmond, Co-Founder and CEO June 18, 2026 Recent scientific studies and thousands of reported cases have linked popular GLP-1 receptor agonist medicationsoriginally designed for Type 2 diabetes but widely prescribed for weight lossto life-altering side effects

State participation in the Medicaid Drug Rebate Program requires coverage of nearly all FDA-approved drugs for medically accepted indications, but weight-loss drugs are included in a small group of drugs that can be excluded from coverage

S.GageF

The shift in revenue sources is dramatic GLP-1 drugs now constitute a majority of Lillys growth